Latest Cetuximab Stories
QUEBEC CITY, July 27, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:Â AEZ) (the "Company") today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.
NEW YORK, July 27, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced completion of patient enrollment in its Phase 3 registration trial of KRX-0401 (perifosine) for the treatment of refractory, advanced colorectal cancer.
A study of more than 1,000 patients with colon cancer that had spread to distant sites found that one in eight was treated with at least one drug regimen that was not recommended.
OMAHA, Neb., May 26, 2011 /PRNewswire/ -- Transgenomic, Inc.
RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients.
Tumor progression is usually ensured by more than one proliferative mechanism.
Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival.
SEATTLE, WA, April 4 /PRNewswire-FirstCall/ - Oncothyreon Inc.
Bowel cancer patients whose tumors contain defects in specific DNA repair systems are much less likely to experience tumor recurrence post surgery, results from a major clinical study have demonstrated.
- The word or words serving to define another word or expression, as in a dictionary entry.